Skip to main content
ATXI
OTC Life Sciences

Avenue Therapeutics Q3: Cash Down to $1.5M, Going Concern Reaffirmed

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Biotech Stocks · Healthcare
Sentiment info
Negative
Importance info
8
Price
$0.429
Mkt Cap
$1.413M
52W Low
$0.15
52W High
$0.97
52W Position info
186% above low
Off High info
56% below high
Rel. Volume
Market data snapshot near publication time

ATXI has more than doubled off its 52-week low of $0.15.

Summary

Avenue Therapeutics reported $1.5 million of cash at September 30, 2026, reaffirmed its going-concern warning, and has no financing capacity, leaving it dependent on a new raise to fund ATX-04.


Key Events · Earnings and Guidance · ATXI

  • Cash Falls to $1.5 Million

    Cash and equivalents were $1.5 million at September 30, 2026, versus $2.9 million at December 31, 2025, after $1.3 million of operating cash burn in the nine months.

  • Going Concern Doubt Reaffirmed

    Management cites substantial doubt about the ability to continue as a going concern within one year, with an accumulated deficit of $107.6 million and no revenue.

  • No Financing Capacity Left

    No ATM sales occurred in the first nine months of 2026; the company says it can no longer use the H.C. Wainwright ATM because its stock was suspended from Nasdaq and now trades on OTCID.

  • Equity Turns Negative

    Total stockholders' equity was a $(75) thousand deficit at September 30, 2026, versus $1.8 million at December 31, 2025, with total liabilities of $1.6 million exceeding total assets of $1.5 million.


Analysis · ATXI · Life Sciences

Cash stood at $1.5 million on September 30, down from $2.9 million at year-end 2025, after $1.3 million of operating burn in the first nine months. Management is explicit: without new capital, the company cannot fund its operating plan for more than 12 months. The ATM that raised $2.1 million in 2025 is now unusable because the stock trades on OTCID rather than Nasdaq. Stockholders' equity has flipped to a $75,000 deficit. That leaves ATX-04 for Pompe disease as the sole asset story, where FDA discussions on a pivotal trial design are ongoing and management says it will then need to raise the money to run the study — making financing, not the science, the near-term constraint.

How filings like this one have moved

In the 30 days to Nov 6, 2026, 45% of the 1400 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.36%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ATXI was trading at $0.43 on OTC in the Life Sciences sector, with a market capitalization of approximately $1.4M. The 52-week trading range was $0.15 to $0.97. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ATXI - Latest Insights

ATXI
Aug 06, 2026, 5:35 PM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.3005
Real-time Price: $0.4289 info
Change: Low Volume info
Market Cap: $1.413M info
ATXI
May 08, 2026, 8:32 AM EDT
Filing Type: 10-Q
Importance Score:
9
Price at Filing: $0.5502
Real-time Price: $0.4289 info
Change: Low Volume info
Market Cap: $1.413M info
ATXI
Feb 23, 2026, 4:06 PM EST
Filing Type: 8-K
Importance Score:
8
Price at Filing: $0.280
Real-time Price: $0.4289 info
Change: Low Volume info
Market Cap: $1.413M info
ATXI
Jan 06, 2026, 4:11 PM EST
Filing Type: SCHEDULE 13D/A
Importance Score:
7
Price at Filing: $0.620
Real-time Price: $0.4289 info
Change: Low Volume info
Market Cap: $1.413M info